Apricus Biosciences has agreed to acquire Topotarget USA, Inc., a subsidiary of Topotarget A/S, a public Danish company. Topotarget USA owns Totect (Dexrazoxane HCl), the only drug approved by the FDA to treat the leakage of chemotherapy drugs from veins into surrounding tissues. This complication is known as anthracycline extravasation, and can lead to infections and tissue death. With the acquisition, Apricus Bio will move into the commercialization and sales of oncology and oncology supporti...